Skip to main content
SpringerLink
Log in

Klinische Pharmakokinetik der Neuroleptika: Ergebnisse und Probleme

  • Conference paper
Neuroleptika Rückschau 1952–1986, Künftige Entwicklungen

Part of the book series: Tropon-Symposium ((BAYERZNS,volume 2))

Zusammenfassung

Fast alle Neuroleptika sind basische amphiphile Substanzen, d. h. sie besitzen einen lipophilen und einen hydrophilen, nämlich geladenen Molekülanteil. Dies bestimmt ihr kinetisches Verhalten, das gekennzeichnet ist durch

  • leichte Penetration durch Lipidmembranen, dadurch hohe Resorptionsquote aus dem Darm

  • Anreicherung in Membranen, daher hohe Konzentration in parenchymatösen Organen, großes scheinbares Verteilungsvolumen

  • hohe Plasmaproteinbindung

  • geringe renale Ausscheidung in unveränderter Form

  • Elimination durch Stoffwechsel, hauptsächlich in der Leber

  • eingeschränkte orale Bioverfügbarkeit infolge Metabolismus beim ersten Durchgang durch Darmwand und Leber (“first-pass effect”).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Altamura AC, Curry SH, Montgomery S, Wiles DH (1985) Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients. Psychopharmacology 87: 30–33

    Article  PubMed  CAS  Google Scholar 

  • Axelsson R, Märtensson E (1978) Relationship between serum concentrations of thioridazine and its main nonconjugated metabolites and clinical response in thioridazine-treated patients. Curr Ther Res 24: 232–242

    Google Scholar 

  • Bianchetti G, Zarifian E, Poirier-Littre MF, Morselli PL, Deniker P (1980) Influence of route of administration on haloperidol plasma levels in psychotic patients. Int J Clin Pharmacol Ther Toxicol 18: 324–327

    PubMed  CAS  Google Scholar 

  • Bolvig Hansen L, Larsen NE (1977) Plasma concentrations of perphenazine and its sulphoxide metabolite during continuous oral treatment. Psychopharmacology 53: 127–130

    Article  Google Scholar 

  • Bolvig Hansen L, Larsen NE (1985) Therapeutic advantages of monitoring plasma concentrations of perphenazine in clinical practice. Psychopharmacology 87: 16–19

    Article  Google Scholar 

  • Bolvig Hansen L, Larsen NE, Gulmann N (1982) Dose-response relationships of perphenazine in the treatment of acute psychoses. Psychopharmacology 78: 112–115

    Article  Google Scholar 

  • Breyer-Pfaff U (1983) Klinische Pharmakokinetik der Neuroleptika. In: Langer G, Heimann H (Hrsg) Psychopharmaka. Grundlagen und Therapie. Springer, Wien New York, S 251–258

    Google Scholar 

  • Breyer-Pfaff U, Brinkschulte M, Rein W, Schied HW, Straube E (1983) Prediction and evaluation criteria in perazine therapy of acute schizophrenics. Pharmacokinetic data. Pharmacopsychiatria 16: 160–165

    Article  PubMed  CAS  Google Scholar 

  • Casper R, Garver DL, Dekirmenjian H, Chang S, Davis JM (1980) Phenothiazine levels in plasma and red blood cells. Their relation to clinical improvement in schizophrenia. Arch Gen Psychiatry 37: 301–305

    Article  PubMed  CAS  Google Scholar 

  • Chang SS, Javaid JI, Dysken MW, Casper RC, Janicak PG, Davis JM (1985) Plasma levels of fluphenazine during fluphenazine decanoate treatment in schizophrenia. Psychopharmacology 87: 55–58

    Article  PubMed  CAS  Google Scholar 

  • Creese I, Snyder SH (1977) A simple and sensitive radioreceptor assay for antischizophrenic drugs in blood. Nature 270: 180–182

    Article  PubMed  CAS  Google Scholar 

  • Curry SH (1968) Determination of nanogram quantities of chlorpromazine and some of its metabolites in plasma using gas-liquid chromatography with an electron capture detector. Anal Chem 40: 1251–1255

    Article  PubMed  CAS  Google Scholar 

  • Curry SH, Whelpton R, de Schepper PJ, Vranckx S, Schiff AA (1979) Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man. Br J Clin Pharmacol 7: 325–331

    PubMed  CAS  Google Scholar 

  • Dahl SG (1976) Pharmacokinetics of methotrimeprazine after single and multiple doses. Clin Pharmacol Ther 19: 435–442

    PubMed  CAS  Google Scholar 

  • Dahl SG, Strandjord RE (1977) Pharmacokinetics of chlorpromazine after single and chronic dosage. Clin Pharmacol Ther 21: 437–448

    PubMed  CAS  Google Scholar 

  • Davis JM, Ericksen SE, Hurt S, Chang SS, Javaid JI, Dekirmenjian H, Casper R (1985) Haloperidol plasma levels and clinical response: basic concepts and clinical data. Psychopharmacol Bull 21: 48–51

    PubMed  CAS  Google Scholar 

  • Dysken MW, Javaid JI, Chang SS, Schaffer C, Shahid A, Davis JM (1981) Fluphenazine pharmacokinetics and therapeutic response. Psychopharmacology 73: 205–210

    Article  PubMed  CAS  Google Scholar 

  • Extein I, Augusthy A, Gold MS, Pottash ALC, Martin D, Potter WZ (1982) Plasma haloperidol levels and clinical response in acute schizophrenia. Psychopharmacol Bull 18: 156–158

    PubMed  CAS  Google Scholar 

  • Extein I, Pottash ALC, Gold MS (1983) Therapeutic window for plasma haloperidol in acute schizophrenic psychosis. Lancet I:1048–1049

    Google Scholar 

  • Forsman A, Öhman R (1976) Pharmacokinetic studies on haloperidol in man. Curr Ther Res 20: 319–336

    PubMed  CAS  Google Scholar 

  • Forsman A, Öhman R (1977) Applied pharmacokinetics of haloperidol in man. Curr Ther Res 21: 396–411

    CAS  Google Scholar 

  • Garver DL, Hirschowitz J, Glicksteen GA, Kanter DR, Mavroidis ML (1984) Haloperidol plasma and red blood cell levels and clinical antipsychotic response. J Clin Psychopharmacol 4: 133–137

    Article  PubMed  CAS  Google Scholar 

  • Goldstein SA, Van Vunakis H (1981) Determination of fluphenazine, related phenothiazine drugs and metabolites by combined high-performance liquid chromatography and radioimmunoassay. J Pharmacol Exp Ther 217: 36–43

    PubMed  CAS  Google Scholar 

  • Hansen CE, Christensen TR, Elley J, Bolvig Hansen L (1976) Clinical pharmacokinetic studies of perphenazine. Br J Clin Pharmacol 3: 915–923

    CAS  Google Scholar 

  • Harris PQ, Brown SJ, Friedman MJ, Bacopoulos NG (1984) Plasma drug and homovanillic acid levels in psychotic patients receiving neuroleptics. Biol Psychiatry 19: 849–860

    PubMed  CAS  Google Scholar 

  • Holley FO, Magliozzi JR, Stanski DR, Lombrozo L, Hollister LE (1983) Haloperidol kinetics after oral and intravenous doses. Clin Pharmacol Ther 33: 477–484

    Article  PubMed  CAS  Google Scholar 

  • Jann MW, Ereshefsky L, Saklad SR (1985) Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokin 10: 315–333

    Article  CAS  Google Scholar 

  • Jorgensen A (1980) Pharmacokinetic studies in volunteers of intravenous and oral cis(Z)-flupentixol and intramuscular cis(Z)-flupentixol decanoate in Viscoleo. Eur J Clin Pharmacol 18: 355–360

    Article  PubMed  CAS  Google Scholar 

  • Jorgensen A (1986) Metabolism and pharmacokinetics of antipsychotic drugs. Progr Drug Metab 9: 111–174

    Google Scholar 

  • Jorgensen A, Andersen J, Bjorndal N, Dencker SJ, Lundin C, Malm U (1982) Serum concentrations of cis(Z)-flupentixol and prolactin in chronic schizophrenic patients treated with flupentixol and cis(Z)-flupentixol decanoate. Psychopharmacology 77: 58–65

    Article  PubMed  CAS  Google Scholar 

  • Knudsen P (1985) Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations. Acta Psychiatr Scand 72 [Suppl 322]: 51–75

    Article  Google Scholar 

  • Knudsen P, Bolvig Hansen L, Auken G, Waehrens J, Hojholt K, Larsen NE (1985a) Perphenazine decanoate vs. perphenazine enanthate: Efficacy and side effects in a 6 week double-blind, comparative study of 50 drug monitored psychotic patients. Acta Psychiatr Scand 72 [Suppl 322]: 15–28

    Article  Google Scholar 

  • Knudsen P, Bolvig Hansen L, Hojholt K, Larsen NE (1985b) Long-term depot neuroleptic treatment with perphenazine decanoate I. Efficacy and side effects in a 12 month study of 42 drug monitored psychotic patients. Acta Psychiatr Scand 72 [Supp] 3221: 29–40

    Article  Google Scholar 

  • Ko GN, Korpi ER, Linnoila M (1985) On the clinical relevance and methods of quantification of plasma concentrations of neuroleptics. J Clin Psychopharmacol 5: 253–262

    Article  PubMed  CAS  Google Scholar 

  • Magliozzi JR, Hollister LE, Arnold KV, Earle GM (1981) Relationship of serum haloperidol levels to clinical response in schizophrenic patients. Am J Psychiatry 138: 365–367

    PubMed  CAS  Google Scholar 

  • May PRA, Van Putten T (1978) Plasma levels of chlorpromazine in schizophrenia. A critical review of the literature. Arch Gen Psychiatry 35: 1081–1087

    Article  PubMed  CAS  Google Scholar 

  • May PRA, Van Putten T, Jenden DJ, Yale C, Dixon WJ (1981) Chlorpromazine levels and the outcome of treatment in schizophrenic patients. Arch Gen Psychiatry 38: 202–207

    Article  PubMed  CAS  Google Scholar 

  • McEvoy JP, Stiller RL, Farr R (1986) Plasma haloperidol levels drawn at neuroleptic threshold doses: A pilot study. J Clin Psychopharmacol 6: 133–138

    Article  PubMed  CAS  Google Scholar 

  • Miller DD, Hershey LA, Duffy JP, Abernethy DR, Greenblatt DJ (1984) Serum haloperidol concentrations and clinical response in acute psychosis. J Clin Psychopharmacol 4: 305–310

    Article  PubMed  CAS  Google Scholar 

  • Möller HJ, Kissling W, Lang C, Doerr P, Pirke KM, Zerssen D von (1982) Efficacy and side effects of haloperidol in psychotic patients: oral versus intravenous administration. Am J Psychiatry 139: 1571–1575

    PubMed  Google Scholar 

  • Moulin MA, Davy JP, Debruyne D et al. (1982) Serum level monitoring and therapeutic effect of haloperidol in schizophrenic patients. Psychopharmacology 76: 346–350

    Article  PubMed  CAS  Google Scholar 

  • Neborsky RJ, Janowsky DS, Perel JM (1982) Red blood cell/plasma haloperidol ratios and antipsychotic efficacy. Psychiatr Res 6: 123–124

    Article  CAS  Google Scholar 

  • Pajerski J, Stiller R, Perel J (1982) Comparison of gas chromatography (GC) and radioimmunoassay (RIA) of haloperidol ( H) and applications in pharmacokinetic studies. Fed Proc 41: 1065

    Google Scholar 

  • Potkin SG, Shen Y, Zhou D, Pardes H, Shu L, Phelps B, Poland R (1985) Does a therapeutic window for plasma haloperidol exist? Preliminary Chinese data. Psychopharmacol Bull 21: 59–61

    PubMed  CAS  Google Scholar 

  • Rivera-Calimlim L, Gift T, Nasrallah HA, Wyatt RJ, Lasagna L (1978) Correlation between plasma concentrations of chlorpromazine and clinical response. Commun Psychopharmacol 2: 215–222

    PubMed  CAS  Google Scholar 

  • Rivera-Calimlim L, Hershey L (1984) Neuroleptic concentrations and clinical response. Ann Rev Pharmacol Toxicol 24: 361–386

    Article  CAS  Google Scholar 

  • Rubin RT, Forsman A, Heykants J, Öhman R, Tower B, Michiels M (1980) Serum haloperidol determinations in psychiatric patients. Comparison of methods and correlation with serum prolactin levels. Arch Gen Psychiatry 37: 1069–1074

    Article  PubMed  CAS  Google Scholar 

  • Sakalis G, Chan TL, Sathananthan G, Schooler N, Goldberg S, Gershon S (1977) Relationships among clinical response, extrapyramidal syndrome and plasma chlorpromazine and metabolite ratios. Commun Psychopharmacol 1: 157–166

    PubMed  CAS  Google Scholar 

  • Schaffer CB, Shahid A, Javaid JI, Dysken MW, Davis JM (1982) Bioavailability of intramuscular versus oral haloperidol in schizophrenic patients. J Clin Psychopharmacol 2: 274–277

    Article  PubMed  CAS  Google Scholar 

  • Shvartsburd A, Dekirmenjian H, Smith RC (1983) Blood levels of haloperidol in schizophrenic patients. J Clin Psychopharmacol 3: 7–12

    Article  PubMed  CAS  Google Scholar 

  • Smith RC, Baumgartner R, Misra CH, Mauldin M, Shvartsburd A, Ho BT, DeJohn C (1984a) Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v. radioreceptor plasma level assays. Arch Gen Psychiatry 41: 1044–1049

    Article  PubMed  CAS  Google Scholar 

  • Smith RC, Baumgartner R, Ravichandran GK, Shvartsburd A, Schoolar JC, Allen P, Johnson R (1984b) Plasma and red cell levels of thioridazine and clinical response in schizophrenia. Psychiatr Res 12: 287–296

    Article  CAS  Google Scholar 

  • Swigar ME, Jatlow PI, Goicoechea N, Opsahl C, Bowers MB Jr (1984) Ratio of serum prolactin to haloperidol and early clinical outcome in acute psychosis. Am J Psychiatry 141: 1281–1283

    PubMed  CAS  Google Scholar 

  • Taylor G, Houston JB, Schaffer J, Mawer G (1983) Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man. Br J Clin Pharmacol 15: 287–293

    PubMed  CAS  Google Scholar 

  • Van Putten T, May PRA, Jenden DJ (1981) Does a plasma level of chlorpromazine help? Psychol Med 11: 729–734

    Article  PubMed  Google Scholar 

  • Van Putten T, Marder R, May PRA, Poland RE, O’Brien RP (1985) Plasma levels of haloperidol and clinical response. Psychopharmacol Bull 21: 69–72

    PubMed  Google Scholar 

  • Wiesel FA, Alfredsson G, Ehrnebo M, Sedvall G (1980) The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects. Eur J Clin Pharmacol 17: 385–391

    Article  PubMed  CAS  Google Scholar 

  • Wiles DH, Gelder MG (1979) Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injection of fluphenazine decanoate. Br J Clin Pharmacol 8: 565–570

    PubMed  CAS  Google Scholar 

  • Wistedt B, Jorgensen A, Wiles D (1982) A depot neuroleptic withdrawal study. Plasma concentration of fluphenazine and flupenthixol and relapse frequency. Psychopharmacology 78: 301–304

    Article  PubMed  CAS  Google Scholar 

  • Wode-Helgodt B, Alfredsson G (1981) Concentrations of chlorpromazine and two of its active metabolites in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine. Psychopharmacology 73: 55–62

    Article  PubMed  CAS  Google Scholar 

  • Wode-Helgodt B, Borg S, Fyrö B, Sedvall G (1978) Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine. Acta Psychiatr Scand 58: 149–173

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. U. Breyer-Pfaff
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. 24, rue des Fossés Saint Jacques, F-75005, Paris, France

    Pierre Pichot

  2. Psychiatrische Klinik der Technischen Universität, Ismaninger Str. 22, D-8000, München 80, Deutschland

    Hans-Jürgen Möller

Rights and permissions

Reprints and permissions

Copyright information

© 1987 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Breyer-Pfaff, U. (1987). Klinische Pharmakokinetik der Neuroleptika: Ergebnisse und Probleme. In: Pichot, P., Möller, HJ. (eds) Neuroleptika Rückschau 1952–1986, Künftige Entwicklungen. Tropon-Symposium, vol 2. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-83188-1_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-83188-1_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-18197-2

  • Online ISBN: 978-3-642-83188-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation